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Abstract
Background: Definitive chemoradiation (dCRT) is considered curative intent treatment for patients with inoperable
or irresectable esophageal cancer. Acute toxicity data focussing on dCRT are lacking.
Methods: A retrospective analysis of patients treated with dCRT consisting of 6 cycles of paclitaxel 50 mg/m2 and
carboplatin AUC2 concomitant with radiotherapy (50.4 Gy\1.8Gy) from 2006 through 2011 at a single tertiary center
was performed. Toxicity, hospital admissions and survival were analysed.
Results: 127 patients were treated with definitive chemoradiation. 33 patients were medically inoperable, 94
patients were irresectable, Despite of a significantly smaller tumor length in inoperable patients grade ≥3 toxicity
was significantly recorded more often in the inoperable patients (44%) than in irresectable patients (20%) (p < 0.05)
Hospital admission occurred more often in the inoperable patients (39%) than in the irresectable patients (22%)
(p < 0.05) Median number of cycles of chemotherapy was five for inoperable patients (p = 0.01), while six cycles
could be administered to patients with irresectable disease. Recurrence and survival were not significantly
different. The odds ratio for developing toxicity ≥ grade 3 was 2.6 (95% CI 1.0-6.4 p < 0.05) for being an
inoperable patient and 1.2 (95% CI 1.0-1.4 p = 0.02) per 10 extra micromol/l creatinine.
Conclusions: Our data show that acute toxicity of definitive chemoradiation is worse in patients with medically
inoperable esophageal carcinoma compared to patients with irresectable esophageal cancer and mainly occurs
in the 5th cycle of treatment. Improvement of supportive care should be undertaken in this more fragile group.
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Background
Esophageal carcinoma is the eighth most common can-
cer worldwide [1]. The total incidence of esophageal
cancer is rising, mainly as the result of a marked in-
crease in the incidence of adenocarcinoma. It is often di-
agnosed in late stages, and approximately 50% of the
patients have potentially curable disease.
In patients who are considered fit for surgery and have
technically resectable disease the treatment of choice is
surgical resection. Outcome of esophageal resection can
be improved by multimodality treatment. A meta-analysis
has shown significant benefit of chemoradiation followed
by over surgery alone for both adenocarcinoma and squa-
mous cell carcinoma. The hazard ratio for all-cause mor-
tality with neoadjuvant chemoradiotherapy versus surgery
alone was 0.81 (95% CI 0.70-0.93; p = 0.002), correspond-
ing to a 13% absolute difference in survival at 2 years [2].
In the Netherlands the preferred radiochemotherapy regi-
men consists of carboplatin plus paclitaxel concurrent
with 41.4 Gy of radiation, which is based on the results of
the Dutch CROSS study which showed a median survival
of 49.4 months in the chemoradiotherapy surgery arm
versus 24 months in the surgery group. The chemoradia-
tion regimen was well tolerated with 7% hematologic
and 13% non hematologic grade 3/4 toxicities, mainly
leukopenia and anorexia [3].
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In contrast to patients with resectable disease, patients
staged irresectable (T4N0-1 M0) by endoscopic ultrason-
ography (EUS) have a very poor prognosis [4,5]. Primary
surgery does not prolong survival and patients can be
treated with chemotherapy, radiation therapy or best sup-
portive care [6,7].
Based on the results of the RTOG 8501 [8] chemoradio-
therapy is superior compared to radiotherapy alone. In
this prospective randomized clinical trial, patients with
squamous cell carcinoma or adenocarcinoma were treated
with chemoradiotherapy (4 cycles of 5-fluorouracil and
cisplatin and radiotherapy (50 Gy at 2 Gy/d) or radiother-
apy alone (64 Gy). The combined modality arm demon-
strated a significant improvement in both median survival
(14 vs. 9 months) and 5-year overall survival (27% vs.
none) with projected 8-year and 10-year survival rates of
22% and 20% respectively.
Only a few studies described the toxicity results of
the definitive chemoradiation for irresectable tumors
(T4N0-1 M0). In a German study 22 patients were treated
with induction chemotherapy with 5FU and cisplatin
followed by concurrent chemoradiation therapy for T4 and
obstructing T3 squamous cell carcinoma of the upper and
midthoracic esophagus. A partial or complete response was
seen in 9 (41%) and 1 (5%) patients, respectively, and 41% of
the patients were alive at 2 years after treatment. The main
toxicities in this cisplatin based chemoradiation scheme
were leukocytopenias (23%) as well as thrombocytopenias
(9%) grade III and IV. A total of 10 patients (45%) had grade
III and IV dysphagia during chemoradiation (in 32% of the
patients this was already preexistent) [9].
Given the favourable toxicity profile of chemoradiation
with carboplatin and paclitaxel in the preoperative set-
ting, a phase II study was performed in the Netherlands
with concurrent chemoradiation with paclitaxel and car-
boplatin as definitive treatment for patients with irre-
sectable esophageal cancer. Durable locoregional control
and palliation was achieved in about half of the patients.
Median overall and disease-free survival were 17 months
and 9 months respectively [10]. The main grade 3–4 tox-
icities were neutropenia (16%) thrombocytopenia (4%),
esophagitis (12%) and (fatigue (8%).
Since 2003 patients with irresectable esophageal can-
cer as well as patients medically unfit for surgery, but
deemed fit for definitive chemoradiation were treated in
our centre with this treatment scheme. The tolerability
of this chemoradiation treatment regimen for medically
inoperable patients has never been described in a sub-
stantial cohort of patients.
Therefore, in this retrospective cohort study we com-
pare acute toxicity of the definitive chemoradiation with
carboplatin and paclitaxel in patients with medically in-
operable esophageal cancer and patients with irresect-
able esophageal cancer.
Methods
Patients and study design
The medical charts of all patients with esophageal and eso-
phagastric junction cancer treated between March 2006
and October 2011 in the Academic Medical Centre with
definitive chemoradiation were retrieved. Treatment strat-
egy was defined during multidisciplinary meetings for all
patients. Patients were treated with carboplatin targeted at
an area under the curve (AUC) of 2 mg per milliliter per
minute and paclitaxel 50 mg per square meter of body sur-
face area. Carboplatin and paclitaxel were administered
intravenously on days 1, 8, 15, 22, 29, and 36. A total radi-
ation dose of 50.4 Gy was given in 28 fractions of 1.8 Gy,
in 5 fractions administered per week. All patients were
treated by means of external beam radiation.
Patients were divided into two groups based on the rea-
son for treatment with definitive chemoradiation: inoper-
able patients and irresectable patients. Inoperable patients
were defined as patients with surgical contraindications
like heart failure NYHA III and IV, FEV1 <1.5 L or WHO
performancescore 3 or 4. Irresectable patients were de-
fined as patients with locally irresectable carcinoma of the
esophagus or gastric junction (T4N0-1 M0) [11], patients
with locally recurrent carcinoma of the esophagus outside
the prior radiation field, a cervical carcinoma of the
esophagus or patients with involvement of celiac or supra-
clavicular lymphnodes (M1a). When more than one rea-
son was given for inoperability the predominant factor is
stated. Patients refusing surgery and treated with dCRT
instead were excluded from analyses.
Data collection
According to national regulations formal ethics approval
for researching human data according was not needed
[12,13]. We recorded clinical, histopathological, labora-
tory and endoscopic data from the hospital records.
At baseline, age, tumor length, comorbidity, body sur-
face area (BSA), Body Mass Index (BMI) and WHO per-
formance score were noted. Furthermore, tumor histology
(squamous carcinoma, adenocarcinoma and other) as well
as baseline creatinine (micromol/liter) and albumin (U/l)
were scored.
Toxicity throughout chemoradiation was scored ac-
cording to Common Terminology Criteria for Adverse
Events version 3.0. Also dose modifications or discon-
tinuation of chemo- and radiotherapy were recorded.
Locoregional recurrences and distant metastasis were de-
fined by proven histology of the recurrent site, or by clinical
signs of recurrent disease combined with progression on CT
scan or PET/CT scan or suspicious endoscopic findings.
Statistical analyses
Descriptive statistics of categorical variables are reported
as total numbers and percentages. Continuous variables
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are reported as means and standard deviation. To assess
whether irresectable and inoperable patients differed in
baseline characteristics unpaired t tests were used for
continuous variables with normal distribution. For vari-
ables with non-normal distribution the Mann Whitney
test was performed. To compare toxicity between the
two groups the chi square test was performed.
To identify other determinants for toxicity than having
inoperable or irresectable esophageal cancer we performed
logistic regression analysis. We selected those determinants
that either differed significantly between the inoperable
and inresectable groups at baseline, and/or showed a sig-
nificant univariable relation with toxicity. These determi-
nants were used in separate multivariable models, each
model including one determinant and the main group fac-
tor (inoperabel versus inresectable).
The Kaplan-Meier method was used to estimate sur-
vival, with the log rank test to determine significance.
All statistical analyses were performed with SPSS (version
19.0). Statistical inferences were based on 2-sided tests with
p < 0.05 considered to be statistically significant.
Results
Patient characteristics
Overall, 127 patients were treated with definitive chemo-
radiation in our institution. Distribution of patients in the
inoperable and irresectable group are listed in Table 1.
Characteristics of these patients are listed in Table 2.
The mean age of patients at diagnosis was 72 years in
the inoperable group and 63 years in the irresectable
group (p < 0.01) Males were predominant in both groups.
Inoperable patients had a significant higher creatinine
compared to irresectable patients (86 micromol/l and 73
micromol/l, respectively; p < 0.05).
The average length of the primary tumor in the inoper-
able group was significantly shorter with a mean tumor
length of 5.1 cm (SD 2.6 cm) (p <0.05). The irresectable
group had a mean tumor length of 6.6 cm (SD 2.7 cm).
Toxicity
Overall grade ≥3 toxicity was observed in 27% of the pa-
tients. Grade ≥3 toxicity occurred significantly more often
in inoperable patients (44%) versus irresectable patients
(20%, p <0.01). The main grade ≥ 3 toxicities were:
leukopenia, neutropenia, esophagitis and fatigue (Table 3).
Table 1 Distribution of patients in inoperable and
irresectable group
Reason inoperable n = 33
Comorbidity cardiovascular n (%) 2 (6%)
Comorbidity respiratory n (%) 14 (42%)
Comorbidity performancestatus n (%) 10 (30%)
Comorbidity other n (%) 7 (2%)
Reason irresectable n = 94
T4a n (%) 15 (16%)
T4b n (%) 9 (10%)
Recurrent carcinoma n (%) 19 (20%
Cervical carcinoma n (%) 9 (10%)
M1a disease n (%) 41 (44%)
Table 2 Baseline characteristics of inoperable and
irresectable patients
Inoperable
group
Irresectable
group
P value
N = 127 33 94
Sex 0.21
Male n (%) 20 (61%) 68 (72%)
Female n (%) 13 (39%) 26 (28%)
Age (years) (mean and SD) 72 (9) 63 (10) 0.00
Range 53-89 25-84
BMI (kg/m2) (mean and SD) 24.1 (5.4) 23.6 (3.6) 0.65
BSA (m2) (mean and SD) 2.0 (0.6) 1.8 (0.2) 0.16
Tumor length (cm)
(mean and SD)
5.2 (2.7) 6.5 (2.7) 0.04
Stage I/II 13 (40.6%) n.a.
Stage III/IV 19 (59.4%) 100%
Missing 1
Histology 0.14
Adenocarcinoma 18 (55%) 35 (37%)
Squamous cell car. 12 (36%) 53 (56%)
NNO 3 (9%) 6 (6%)
Laboratory
Creatinine μmol/l (median
and IQR)
79 (64–105) 70 (60–82) 0.03
Albumin U/l (mean and SD) 43 (4) 43 (4) 0.99
Hemoglobin mmol/l
(mean and SD)
8.6 (1.0) 8.4 (1.0) 0.38
SD: standard deviation.
IQR interquaertile range.
n.a. not applicable.
Table 3 Grade ≥ 3 toxicity in inoperable and irresectable
patients
Inoperable group Irresectable group
Number of patients (%) n = 33 n = 94
Anorexia 0 (0) 1 (1)
Diarrhea 1 (3) 0 (0)
Fatigue 2 (6) 3 (3)
Leukopenia 6 (18) 3 (3)
Neutropenia 3 (9) 0 (0)
Oesophagitis 5 (15) 9 (10)
Esophageal perforation 0 (0) 1 (1)
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Six patients died during chemoradiation, one because
of neutropenic sepsis, and five because of cardiac failure
(two patients from the inoperable group and four pa-
tients from the irresectable group).
Overall 26% of patients were admitted non-electively
to the hospital because of treatment toxicity. Non-
elective hospital admission was observed significantly
more often in the inoperable group (39% of patients)
compared to the irresectable group (22%, p < 0.05). The
most important reasons for hospital admission were de-
hydration and neutropenic fever.
In both groups full radiation doses could be adminis-
tered to the majority of patients (85% of inoperable pa-
tients, 93% of irresectable patients, p = 0.19). However,
51% of patients with inoperable esophageal cancer and
27% of irresectable patients did not complete six cycles
of chemotherapy (p = 0.01). Median number of cycles of
chemotherapy was five for inoperable patients while on
average six cycles could be administered to patients with
irresectable disease (p = 0.01) (Table 4).
To assess the influence of other determinants for tox-
icity we performed logistic regression analysis. Due to the
relative small number of events (presence of grade ≥ 3 tox-
icity is 20-44%), extensive multivariable analysis was not
possible. Age, creatinine, tumor length and T4 stadium
(yes or no) differed significantly between the two groups
(Table 2). Results of the univariate analysis between the
baseline determinants and toxicity are shown in Table 5.
Univariable prognostic factors for grade ≥ 3 toxicity were
being an inoperable patient, age and creatinine level.
Table 6 shows the results of the multivariable analyses
correcting for the effect of age, creatinine, tumor length
and tumor stadium. Prognostic factors for grade ≥ 3 tox-
icity were being an inoperable patient (p = 0.045) and a
high creatinine level (p = 0.021). The odds ratio for inop-
erable patients developing grade ≥ 3 toxicity was 2.68
(confidence interval 1.01-6.77.5). The increased odds for
developing toxicity per 10 extra micromol/l creatinine
was 1.23 (CI 1.01-1.45). After correction for the effect of
age (Table 6) and tumor length (Table 6) the prognostic
effect of inoperable patient on toxicity showed a trend
for significance (p<. 10) and the odds ratio was high
(>2.4) in all four corrected analyses.
Local recurrence and/or metastasis
Overall, local recurrence occurred in 42% of the patients
and distant metastasis in 44% of the patients. No signifi-
cant difference in local recurrence rate was observed be-
tween inoperable (27%) and irresectable patients (47%)
(p = 0.12), nor for distant metastasis (p = 0.12; inoperable
31%, Irresectable 48%). 51% patients with local recur-
rence had synchronous distant metastasis.
Survival
Median follow up was 44.5 months in the inoperable
group and 51.9 months in the irresectable group. Survival
in the inoperable and irresectable group was not signifi-
cantly different (median overall survival 17.1 months
versus 17.4 months, respectively (p = 0.89).
Discussion
To our knowledge this is the largest retrospective study
reporting on toxicity of definitive chemoradiation in pa-
tients with inoperable and irresectable esophageal can-
cer. We observed a significantly higher grade ≥ 3 toxicity
in the patients that were medically inoperable compared
Table 4 Toxicity and completion of treatment in
inoperable and irresectable patients
Inoperable
group
Irresectable
group
P value
Number of patients 33 94
Toxicity grade≥ 3 14 (44%) 17 (20%) 0.01
WHO performance score≥ 3 14 (45%) 21 (25%) 0.04
Hospital admittance (%) 13 (39%) 19 (22%) 0.048
Hospital stay (days) (IQR) 0 (0–5) 0 (0) 0.11
Chemotherapy complete (%) 16 (49%) 64 (73%) 0.01
Radiotherapy complete (%) 28 (85%) 87 (93%) 0.19
Median cycles (IQR) 5 (4–6) 6 (5.5-6.0) 0.00
Table 5 Univariate analysis, determinants for developing
toxicity grade ≥3
Variable Odds ratio p value 95% confidence interval
Inoperable patient 3,115 0,011 1,294-7,463
Age 1,049 0.036 1,003-1,098
Kreatinine 1,023 0.007 1,006-1,040
BMI 0,986 0.783 0,891-1,091
Tumor length 0,958 0,638 0,801-1,146
T4 stadium 1,169 0,755 0,438-3,122
Albumin 1,025 0,770 0,869-1,209
Table 6 Multivariate odds ratio’s for determinants for
developing grade ≥3 toxicity
Variable Odds
ratio
95% confidence
interval
p value
Model 1 Creatinine
(per 10 micromol/l)
1.213 1.027 1.432 0.023
Inoperable patient 2.551 1.021 6.369 0.045
Model 2 Age 1.034 0.985 1.084 0.174
Inoperable patient 2.457 0.965 6.289 0.059
Model 3 Tumor length 0.986 0.822 1.183 0.877
Inoperable patient 2.410 0.906 6.410 0.078
Model 4 Tumor stadium 1.560 0.501 4.856 0,443
Inoperable patient 3.704 1.307 10.526 0.014
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to patients that were irresectable, resulting in signifi-
cantly more hospital admissions and incomplete admin-
istration of chemotherapy.
Interestingly in our series the patients with inoperable
esophageal carcinoma had a significantly shorter tumor
length and consequently a smaller radiation field. Fur-
thermore in the inoperable group 40% of the patients
had low stage disease with stadium I-II disease. In des-
pite of a smaller radiation field and lower tumor stage
the observed toxicity was significantly higher.
In the literature a range of toxicity grade 3 or higher
in definitive chemoradiation is observed from 11% to
50% of the patients depending on the proportion of pa-
tients with T4 disease [14-17]. Of note, the majority of
these studies used the 5FU cisplatin scheme for which
the main observed toxicities were neutropenia, mucosi-
tis, diarrhoea and neuropathy [3,10,14,15].
In order to complete the scheduled chemotherapy tox-
icity grade ≥ 3 should be minimized and hospital admission
reduced. The most important reasons for the majority of
hospital admissions were dehydration as a result of muco-
sitis or esophagitis and neutropenic fever [16].
To prevent dehydration the start of enteric feeding in an
early stage could be a feasible treatment option. Moreover,
during chemotherapy administration, from cycle 5 onwards
standard extra intravenous fluid suppletion could be con-
sidered. Finally, the introduction of prophylactic quino-
lones, starting from the fifth cycle, could be considered to
prevent neutropenic fever in this patient population.
Failure after treatment of esophageal cancer in our
series concerns both local recurrence and distant metas-
tases in comparable frequencies without significant dif-
ferences between inoperable patients and irresectable
patients. The increased locoregional and distant recur-
rence rate (although not significant) in irresectable pa-
tients reflect the higher tumor stage in this group.
Therefore, the lower toxicity in the irresectable patient
cannot be explained by favourable tumor characteristics
or smaller radiation field sizes. Half of the patients with
distant failure have concurrent locoregional recurrence.
This suggests that not only optimization in the adminis-
tration of chemotherapy could be instrumental in the
improvement of treatment outcome in patients with
esophageal cancer receiving definitive chemoradiation, but
also approaches aimed at reducing the risk of local relapse.
For example, an esophagectomy after definitive chemora-
diation or an integrated boost on the primary tumor could
improve local control. These approaches are subject of on-
going Dutch studies. (NTR 3060, NTR3532).
Some limitations to our study should be noted. Data
were retrospectively collected which may have resulted
in an underestimation of toxicity occurrence. Further-
more, toxicity grade 1 and 2 were not scored in detail.
The study reports on a single institute experience, which
may not be representative of all practices that use the
same chemoradiation scheme. Finally, the focus of this
research was acute toxicity of definitive chemoradiation.
Although survival between the two groups was not sig-
nificantly different between the inoperable and irresect-
able group no definitive conclusions on survival can be
drawn from this study.
Conclusion
This is the first large study reporting on grade 3–4 tox-
icity of definitive chemoradiation with carboplatin and
paclitaxel in patients with inoperable or irresectable
esophageal cancer. Our data show that toxicity is worse
in the inoperable group compared to the irresectable
group and mainly occurs in the 5th cycle of treatment.
Therefore, improvement of supportive care should be
undertaken in this more fragile group to minimize side
effects, preventing incomplete administration of chemo-
therapy, and thereby possibly prolonging survival.
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